Venous Thrombosis Prophylaxis in Medical Patients

Anderson FJ Wheeler H Goldberg R A population-based perspective of the hospital incidence and case-fatality rates of venous thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Intern Med 1991; 151: 933–38.

Salzman E Davies G. Prophylaxis of venous thromboembolism. Analysis of cost-effectiveness. Ann Surg 1980; 191: 207–18.

Collins R Scrimgeour A Yusuf S Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162–73.

Anderson F Wheeler B Goldberg R Hosmer D. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660–64.

Halkin H Goldberg J Modan M Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 561–65.

Harenberg J Roebruck P Stehle G Biegholdt M Heene D HESIM Group. Heparin study in internal medicine (HESIM): Design and preliminary results. Thromb Res 1992; 68: 33–43.

McCarthy S Robertson D Turner J Hawkey C. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; ii: 800–801.

McCarthy S Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 84–88.

Turpie A Hirsh J Jay R Double-blind randomized trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; i: 523–26.

Nicolaides A Kakkar V Renney J Kidner P Hutchison D Clarke M. Myocardial infarction and deep-vein thrombosis. Br Med J 1971; 1: 432–34.

Handley A. Low-dose heparin after myocardial infarction. Lancet 1972; ii: 623–24.

Warlow C Terry G Kenmure A Beattie A Ogston D Douglas A. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973; ii: 934–36.

Wray R Maurer B Shillingford J. Prophylactic anticoagulant therapy in the prevention of calf-vein thrombosis after myocardial infarction. N Engl J Med 1973; 288: 815–17.

Warkentin T Levine M Hirsh J Heparin-induced thrombocytopenia in patients with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–35.

Dahan R Houlbert D Caulin C. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986; 16: 159–64.

Elias A Milandre L Lagrange G Prévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients). Rev Med Intern 1990; XI: 95–98.

Prins M Gelsema R Sing A van Heerde L den Ottolander G. Prophylaxis of deep venous thrombosis with a low-molecular weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989; 19: 245–50.

Turpie A Gent M Côte R A low molecular weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Intern Med 1992; 117: 353–57.

Nurmohamed M Rosendaal FS Buller HR Low-molecular weight heparin versus standard heparin in general and orthopedic surgery: A meta-analysis. Lancet 1992; 340: 152–56.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235–46.

Warlow C Ogston D Douglas A. Venous thrombosis following strokes. Lancet 1972; i: 1305–306.

Denham M Farran H James G. The value of I(125) fibrinogen in the diagnosis of deep vein thrombosis in hemiplegia. Age Ageing 1973; 2: 207–10.

Gibberd F Gould S Marks P. Incidence of deep vein thrombosis and leg oedema in patients with strokes. J Neurol Neurosurg Psychiatry 1976; 39: 1222–25.

Warlow C Ogston D Douglas A. Deep venous thrombosis of the legs after strokes. Br Med J 1976; 1: 1178–83.

Bounds J Wiebers D Whisnant J Okazaki H. Mechanisms and timing of deaths from cerebral infarction. Stroke 1981; 12: 474–77.

Bornstein N Norris J. Deep vein thrombosis after ischemic stroke: Rationale for a therapeutic trial. Arch Phys Med Rehabil 1988; 69: 955–58.

Scmidt E Smirnov V Ryabova V. Results of the seven-year prospective study of stroke patients. Stroke 1988; 19: 942–49.

Gillum R. Pulmonary embolism and thrombophlebitis in the United States, 1970–1985. Am Heart J 1987; 114: 1262–64.

Balleisen L Bailey J Epping P. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I: Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill using and menopause. Thromb Haemost 1985; 54: 475–79.

Tracy R Bovill E Fried L. The distribution of coagulation factors VII, VIII and fibrinogen in adults over the age of 65 years: Results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2: 509–19.

Bauer K Weiss L Sparrow D. Aging-associated changes in indices of thrombin generation and protein C activation in humans: Normative aging studies. J Clin Invest 1987; 80: 1527–34.

Ranby M Bergsdorf N Nilsson T. Age dependence of tissue plasminogen activator concentrations, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160–65.

Landi G D'Angelo A Boccardi E Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. Arch Neurol 1992; 49: 279–83.